AZ 1st-line lung cancer immuno-oncology programme
17 January 2017 07:00 ASTRAZENECA EXPANDS 1ST-LINE LUNG CANCERIMMUNO-ONCOLOGY PROGRAMME OPPORTUNITIES Refined endpoints and statistical analysis plan in the Phase III MYSTIC trial China regulatory submission opportunity strengthened with the expansion of the Phase III NEPTUNE trial and the initiation of the new Asia-focused Phase III PEARL trial AstraZeneca today provides an update on its Immuno-Oncology (IO) late-stage clinical development programme in 1st-line non-small cell lung cancer (NSCLC), including a refinement of the Phase III MYSTIC trial. The MYSTIC trial was